Crispr Therapeutics Revenue vs. EBITDA
| CRSP Stock | USD 50.84 1.53 3.10% |
Total Revenue | First Reported 2014-12-31 | Previous Quarter 517 K | Current Value 602 K | Quarterly Volatility 149.5 M |
For Crispr Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Crispr Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Crispr Therapeutics AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Crispr Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Crispr Therapeutics AG over time as well as its relative position and ranking within its peers.
Crispr |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Revenue Per Share 2.446 | Quarterly Revenue Growth (0.99) | Return On Assets (0.1) | Return On Equity (0.13) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Crispr Therapeutics EBITDA vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Crispr Therapeutics's current stock value. Our valuation model uses many indicators to compare Crispr Therapeutics value to that of its competitors to determine the firm's financial worth. Crispr Therapeutics AG is rated fifth in revenue category among its peers. It is rated below average in ebitda category among its peers . At this time, Crispr Therapeutics' Total Revenue is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Crispr Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Crispr Revenue vs. Competition
Crispr Therapeutics AG is rated fifth in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 247.65 Billion. Crispr Therapeutics adds roughly 371.21 Million in revenue claiming only tiny portion of equities under Health Care industry.
Crispr EBITDA vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Crispr Therapeutics |
| = | 371.21 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Crispr Therapeutics |
| = | (202.7 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Crispr EBITDA Comparison
Crispr Therapeutics is currently under evaluation in ebitda category among its peers.
Crispr Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Crispr Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Crispr Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Crispr Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Crispr Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.9 M | 2 M | |
| Operating Income | -222.5 M | -211.4 M | |
| Net Loss | -153.6 M | -161.3 M | |
| Income Before Tax | -150.7 M | -158.3 M | |
| Total Other Income Expense Net | 71.8 M | 75.4 M | |
| Net Loss | -585.2 M | -555.9 M | |
| Net Loss | -153.6 M | -161.3 M | |
| Income Tax Expense | 2.9 M | 3 M | |
| Interest Income | 4.9 M | 9 M | |
| Non Operating Income Net Other | 20.4 M | 11.6 M | |
| Change To Netincome | 127 M | 133.3 M | |
| Net Loss | (1.94) | (2.04) | |
| Income Quality | 1.70 | 1.78 | |
| Net Income Per E B T | 1.02 | 0.81 |
Crispr Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Crispr Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Crispr Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Crispr Therapeutics' important profitability drivers and their relationship over time.
Use Crispr Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Crispr Therapeutics Pair Trading
Crispr Therapeutics AG Pair Trading Analysis
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Crispr Therapeutics position
In addition to having Crispr Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Energy Thematic Idea Now
Alternative Energy
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.